Founded in 2019, PLL Therapeutics, a clinical-stage biopharmaceutical company, is spearheading a unique therapeutic approach for treating the root cause of autoimmune and neurodegenerative diseases, based on its groundbreaking polypeptide delivery platform. The company focuses on restoring gut integrity through the delivery of targeted Small-Chain Fatty Acids (SCFAs) to gut epithelial cells and the Blood-Brain Barrier (BBB), helping restore the normal function of cells lining the gut, as well as the BBB. Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease, is the company’s first indication.

In parallel, PLL Therapeutics is validating a panel of specific biomarkers for clinical use that will enable the first-ever early-stage diagnosis of ALS. This development includes companion diagnostics for ALS and other neurodegenerative disorders.  

PLL Therapeutics’ platform technology aims to redefine the standard of care in how patients living with ALS are treated and monitored in clinical follow-up, as well as prevent diseases linked to dysbiosis of the gut microbiota.

PLL Therapeutics is led by a highly experienced and entrepreneurial management team with decades of expertise in infectious diseases, rare diseases, and CNS (Central Nervous System). The company has successfully completed a phase I trial in patients with ALS and a phase II trial will take place in Australia and New Zealand in 2026.

The company is located near Bordeaux, France.

PLL Therapeutics

Org chart

Teams

Offices